**Genetic architecture of brain age and its casual relations with brain and mental disorders**

Esten H. Leonardsen, MS[1,2], Didac Vidal-Piñeiro, PhD[1], James M. Roe, PhD[1], Oleksandr Frei,

PhD[2], Alexey A. Shadrin, PhD[2,3], Olena Iakunchykova, PhD[1], Ann-Marie G. de Lange, PhD[4,5,6],

Tobias Kaufmann, PhD[2,7], Bernd Taschler, PhD[8], Stephen M. Smith, PhD[8], Ole A. Andreassen,

MD, PhD[2,3], Thomas Wolfers, PhD[2,4,7], Lars T. Westlye, PhD[2,3,4], Yunpeng Wang, PhD[1,*]

1 Center for Lifespan Changes in Brain and Cognition (LCBC), Department of Psychology,

University of Oslo, 0317 Oslo, Norway

2 NORMENT, Division of Mental Health and Addiction, Oslo University Hospital & Institute of

Clinical Medicine, University of Oslo, 0317 Oslo, Norway

3 K.G. Jebsen Centre for Neurodevelopmental disorders, University of Oslo, Oslo, Norway

4 Department of Psychology, University of Oslo, 0317 Oslo, Norway

5 LREN, Centre for Research in Neurosciences, Department of Clinical Neurosciences, Lau-

sanne University Hospital (CHUV) and University of Lausanne, 1015 Lausanne, Switzerland

6 Department of Psychiatry, University of Oxford, OX1 2JD Oxford, UK

7 Department of Psychiatry and Psychotherapy, Tübingen Center for Mental Health,

University of Tübingen, 72074 Tübingen, Germany

8 Wellcome Centre for Integrative Neuroimaging (WIN FMRIB), University of Oxford, OX3

9DU Oxford, United Kingdom

[*] Corresponding author:

Yunpeng Wang,

Department of Psychology, University of Oslo,

Forskningsveien 3A, Harald Schjelderups hus, 0373 Oslo, Norway.

Email: yunpeng.wang@psykologi.uio.no.

Tel: +47 4655 9652

Running title: Brain age and mental disorders

**Abstract (**178 words**)**

The difference between chronological age and the apparent age of the brain estimated from

brain imaging data — the brain age gap (BAG) — is widely considered a general indicator of

brain health. Converging evidence supports that BAG is sensitive to an array of genetic and

non-genetic traits and diseases, yet few studies have examined the genetic architecture and

its corresponding causal relationships with common brain disorders. Here, we estimate BAG

using state-of-the-art neural networks trained on brain scans from 53,542 individuals (age

range 3-95 years). A genome-wide association analysis across 28,104 individuals (40-84 years)

from the UK Biobank revealed eight independent genomic regions significantly associated

with BAG ($p<5\times10^{-8}$) implicating neurological, metabolic, and immunological pathways –

among which seven are novel. No significant genetic correlations or causal relationships with

BAG were found for Parkinson's disease, major depressive disorder, or schizophrenia, but

two-sample Mendelian randomization indicated a causal influence of AD ($p=7.9\times10^{-4}$) and

bipolar disorder ($p=1.35\times10^{-2}$) on BAG. These results emphasize the polygenic architecture of

brain age and provide insights into the causal relationship between selected neurological and

neuropsychiatric disorders and BAG.

**Introduction**

Over the last decade, brain age has emerged as a promising measure of overall brain health[1, 2]. To estimate brain age, machine learning models are applied to brain imaging data to learn visual patterns characteristic of different ages[3, 4]. The difference between predicted brain age and chronological age is termed the brain age gap (BAG) and indicates deviation from a normative aging trajectory, a potential health indicator. Earlier studies have found a large variation in the predicted brain age of individuals with the same chronological age, and that these interindividual variations correlate with neurological and mental disorders[5-7], such as dementia[6, 8], schizophrenia (SCZ)[9, 10], major depressive disorder (MDD)[11], and also mortality[7, 12]. In addition, biological, environmental and lifestyle factors associated with these disorders have been reported to correlate with BAG, for example infections[13, 14], smoking[5], physical activity[15], and education level[16].

Genetic differences have been shown to explain a sizeable portion of interindividual variation in BAG. Twin-based heritability for BAG has been estimated to be as high as 0.66[17], and single nucleotide polymorphism (SNP)-based heritability estimates are also relatively high — around 0.2 [6, 18]. Earlier gene-discovery efforts investigating genetic associations with BAG have found and examined two genomic loci in detail: one on chromosome 1 containing the potassium channel gene, *KCNK2*, and one in the chromosome 17 inversion region (17q21.31)[18, 19]; Genetic variants in these two regions together explain a negligible fraction of estimated SNP-heritability[18]. These results suggest that existing GWAS were potentially underpowered to fully characterize the genetic architecture, supported by studies using a conditional false discovery rate-based models yielding a larger set of associations[6].

Furthermore, Smith *et al.*[20] found a rich set of associations when investigating different facets

of a multimodal brain age, suggesting that the interplay between genetic variants is complex.

Although BAG has been frequently associated with mental disorders, the underlying

genetic basis for the observed association has seldom been investigated, possibly due to

incomplete knowledge of the genetic architecture of the former. Furthermore, the causal

relationships between BAG and brain disorders remain untapped. Mendelian randomization

(MR) has become an attractive tool to interrogate cause-effect relationships between risk

factors or disorders[21]. Two-sample MR models have been used to infer causal relations

between hundreds of traits or diseases[22]. However, MR analyses targeting the causal relations

between BAG and brain disorders and associated traits have been lacking[23].

In the present work, we improve the yield of genetic associations for BAG using three

strategies: First, we estimate brain age using a state-of-the-art deep neural network

architecture (SFCN-reg) trained on one of the largest samples assembled to date[5]. Then we

perform a GWAS for BAG on out-of-sample predictions for a portion of the UK Biobank v3

data containing 28,104 unrelated individuals, about eight thousand more than earlier studies.

Finally, we use two-sample MR to assess the genetic and causal relations between BAG and

SCZ, bipolar disorder (BIP), Alzheimer's disease (AD), MDD, and Parkinson's disease (PD).

## Methods

**Sample**

All datasets used in the present study have been obtained from previously published studies

which have been approved by their respective institutional review board, research ethic

committee or other relevant ethic organizations.

We used UK Biobank imaging data (UKB, accession number 27412) released in 2019

in combination with a pre-compiled dataset from various sources (**Supplementary Table S1**)

for brain age model training and estimation. For the downstream genetic analyses, we started

with the initial 40,330 UKB participants that had undergone at least one brain scan (using

baseline scans where more were available). We excluded those with recorded brain injury or

neurological or psychiatric conditions, those failing standard image quality checks[5], those

whose genetic data failed quality check by the UKB team, in addition to participants who

withdrew consent. Among related participants (UKB-reported kinship coefficient >0), only

one was included in the study. In total, 28,104 unique participants remained.

**Brain age estimation**

A minimal preprocessing protocol was applied to all raw T1-weighted brain MRI images before

brain age estimation[5]: The auto-recon pipeline from FreeSurfer 5.3[24] was used to remove non-

brain tissue. The resulting volumes were reoriented to the standard FSL[25] orientation using

fslreorient2std, and linearly registered to the 1 mm FSL (version 6.0) MNI152 template using

FLIRT[26], with 6 degrees of freedom. For efficiency, during model fitting, we cropped a central

cube spanning the voxels 6:173, 2:214, and 0:160 in the sagittal, coronal, and axial dimensions,

respectively. Before modelling, all voxel intensities were normalized by a constant factor to

produce values in the range [0, 1].

The data from all sources (**Supplementary Table S1** and UKB) were split into five

equally-sized and disjoint folds with comparable age-ranges and sex distributions. Four of

these folds were used for fitting the brain age model, and out-of-sample estimates were

computed for the remaining fold. This procedure was repeated five times, resulting in out-of-

sample brain age estimates for all participants. Next, BAG was calculated by subtracting

chronological age from estimated brain age. The subsequent analyses were performed on the

out-of-sample estimates of the UKB data (**Supplementary Table S2**).

**Genome-wide association study**

Imputed genotypes for the 28,104 participants were obtained from UKB (Category 100314,

for further details see[27]). We excluded SNPs based on missing rate (>0.02), the Hardy-

Weinberg Equilibrium test ($p<10^{-6}$) and minor allele frequency (MAF; < 0.01). In total, ≈8.6

million SNPs were analyzed. Since we have observed apparent differences in predicted brain

age across folds (**Supplementary Fig. S1**), a GWAS was performed on each hold-out fold

separately using PLINK 1.90 beta[28]. The additive genetic model was assumed, and

chronological age, sex and the top ten principal components were included as covariates,

accounting for population structure. Association results for each hold-out fold of UKB along

with distributions of BAG are shown in **Supplementary Figure S1**. These association results

were then meta-analyzed using the inverse variance weighted model implemented in PLINK

to identify SNPs that are associated with BAG. **Supplementary Figure S2** shows the

association QQ plot which indicated no noticeable genomic inflation.

**Associated regions and genes**

Association results were 'clumped' by the FUMA[29] web-service using the linkage disequilibrium (LD) structure from the 1000 Genomes projects phase 3 EUR dataset (1KGp3), with parameters *–clump-p 5e-8 –clump-2 1e-6 –clump-r2 0.1.* The standard 250 kilo-bases (kb) were used as the inter-region distance threshold. Genes whose genomic coordinates located within the boundaries of each region were assigned to the corresponding region. SNPs with the smallest association p-values were taken as the lead SNPs for the corresponding regions. In addition, the gene that is closest to each lead SNP by genomic position was annotated using the Ensembl tool VEP[30] (**Table 1**).

Associated regions were fine-mapped using the FINEMAP[31] program. The LD structure from 1KGp3 was also used in this analysis. The default settings of FINEMAP were used, which compares causal models assuming one causal variant in each region to that assuming two, based on the estimated posterior probabilities ($PP\_1$ versus $PP\_2$). FINEMAP ranks all possible configurations in each model presented as 95% credible sets. The confidence of a variant belonging to a set was evaluated by posterior probabilities of inclusion (PPI). In the case of assuming one causal variant, each single variant was assigned a PPI. In the two causal variants cases, each pair of variants was assigned a PPI.

**Post-GWAS annotations**

Both FUMA and Garfield[32] were used for annotating associated SNPs. First, SNPs were assigned to genic elements (*e.g.*, exon, intron, 3' and 5' untranslated regions, intergenic regions, etc.), and the enrichment of this assignment was tested by hypergeometric test (FUMA) or logistic regression models (Garfield). Expression levels of annotated genes to the associated SNPs were inspected in each of the 54 tissue types from the GTEx v8 dataset[33].

Detailed biological functions for proteins coded by these genes were manually searched in

the NCBI Entrez Gene database[34] and the UniProtKB database[35].

**Genetic correlations between BAG and disorders**

GWAS summary data for four disorders (SCZ[36], BIP[37], MDD[38], and AD[39]) were obtained from

the Psychiatric Genomics Consortium (PGC, https://med.unc.edu/pgc/download-results). For

each GWAS, the association results for European ancestral samples excluding samples from

23andMe were used (SCZ: n case=67,390, n control=94,015; BIP: n case=41,917, n

control=371,549; MDD: n case=59,851, n control=113,154; AD: n case=71,880, n

control=383,378). The PD GWAS results were obtained from the fixed-effect meta-analysis

performed by the International Parkinson Disease Genomics Consortium (IPDGC, n

case=33674, n control=449056)[40].

Before post-GWAS analysis we processed the results from all GWAS using a standard

protocol. Specifically, SNPs having a MAF <0.05, or imputation INFO <0.5, or ambiguous allelic

coding (A/T, or C/G) were removed from subsequent analyses. The LD score model (ldsc)[41]

was applied to estimate SNP-heritability and genetic correlations between BAG and disorders.

Only high-quality SNPs published in the HapMap3 dataset were used for estimation. The LD

score derived from the 1KGp3 was used as input to ldsc. The Benjamini-Hochberg False

Discovery Rate (FDR) procedure was used to correct for multiple testing across disorders

(FDR-corrected p<0.05 was considered statistically significant).

To visualize polygenic enrichment, conditional QQ plots[42, 43] were made for BAG versus

each disorder. In these plots, the QQ curves for the association statistics (-log10 p-values) for

BAG were stratified by the corresponding association strength for the conditioned disorder.

As the association strength to the conditioned disorder increases, a successive leftward

deflation in these curves indicates polygenic enrichment. Similarly, conditional QQ for each

disorder versus BAG shows polygenic enrichment in the reverse direction.

**Two-sample Mendelian randomization**

To study the cause-effect relations between BAG and the five disorders, two sets of MR

analyses were performed. The first set, using standard models, included the inverse-variance

weighted model (IVW)[44], weighted median (wMed)[45], Egger regression (Egger)[46] and MR-

PRESSO (PRESSO)[47]. For these analyses, only genome wide significant SNPs ($p < 5 \times 10^{-8}$) to the

exposure traits or disorders were used as potential instruments. The PLINK program and the

LD structure of 1KGp3 dataset were used to select instruments with the following parameters,

*--clump-kb 500 kb, --clump-p1 $5 \times 10^{-8}$*, and *--clump-r2 0.01*. The TwoSampleMR package[19] was

used for data harmonization and causal inference for the IVW, wMed and Egger models. The

same harmonized datasets were used as input to the MR-PRESSO software to assess outliers

that may artificially affect MR estimates, *i.e.*, SNPs that show horizontal pleiotropy to both

BAG and disorders. Harmonized instrumental SNPs are shown in **Supplementary Tables S6**-

**S15.**

196           The second set of models included the robust adjusted profile score (RAPS)[48] and the

CAUSE models[49]. These models can make use of SNPs that show a suggestive level of

association ($p < 10^{-3}$) with exposure to increase statistical power without incurring weak

instrument bias in estimation. While both models control for horizontal pleiotropy, CAUSE

directly tests for a shared (correlated horizontal pleiotropy) versus a causal model for each

relation[49]. Instead of estimating causal effects, CAUSE provides z scores for such tests;

negative z scores suggest the existence of a causal relation and positive suggest otherwise.

The same instrument selection procedures used in the first set of models were used here,

except that $10^{-3}$ was taken as the cut-off for selecting instruments, *i.e. –clump-p1 $10^{-3}$*.

As each of the six MR models has different assumptions that are difficult to verify in

real data, a majority vote ensemble scheme was used to make conclusions for the existence

of cause-effect relations: specifically, only when four or more models indicated a cause-effect

relation (FDR adjusted p<0.05) was such a relation considered causal.

In addition to applying multiple MR models, GWAS results for height measured for

European samples[50] (n=253,288; https://portals.broadinstitute.org/collaboration/giant/), for

AD diagnosed in a Japanese sample[51] (n case=3,962 and n control=4,047) and an African

sample[52] (n case=2,784 and n control=5,222) and for BIP diagnosed in a Japanese sample[53](n

case=2,964 and n control=61,887) were used to corroborate MR findings. As commonly done

in genetic studies, height was used as a negative exposure control to test if population

stratification could generate spurious causal effects [54]. The non-European GWAS data were

used to test if any observed causal effects generalize across ancestry groups, although with

significantly smaller sample sizes.

**Results**

We obtained accurate brain age estimates; mean absolute errors (MAEs) in each of the five

disjoint folds were consistently below 2.5 years (**Supplementary Table S2**). This was consistent

when we split the dataset into different subsets based on covariates (MAE = 2.40 in females

compared to 2.53 in males; 2.40 in the youngest half compared to 2.52 in the oldest), although

we observed a slight age bias (**Supplementary Figure S9**). Based on the meta-analyzed GWAS

results, we estimated a SNP heritability of 0.27 (standard error (SE)=0.036) for BAG (**Methods**).

Our estimate is comparable to or higher than the two previously reported estimates (0.26,

SE=0.044[6]; 0.19, SE=0.02[18]).

We identified eight independent genomic loci significantly associated with BAG (**Fig. 1**

**a,b** and **Table 1**). Associations of lead SNPs in these regions to BAG are highly consistent in

directions and effect sizes across the five folds (**Supplementary Table S3**). Among these loci,

the one in the inversion region on chromosome 17 (lead SNP rs2106786), including the *MAPT*

gene, has been previously reported[18, 19], although indexed by a different SNP (rs2435204). This

SNP was also highly significant in our analysis (p=5.4x10$^{-21}$, beta=0.27 years, effective-

allele=G). The locus containing the *RUNX2* gene (lead by rs2790102: p=8.92x10$^{-9}$, beta=-0.15

years, effective-allele=A), which showed suggestive significance in Jonsson *et al.*[18], was

genome-wide significant in the present study. The *RUNX2* gene codes for a master

transcription factor which plays a critical role in skeletal development[55]. Among the remaining

six novel loci, the rs79107704-A allele showed the largest association with BAG; one copy of

this allele was associated with an average increase in brain age of 0.63 years (**Table 1**). This

SNP is located 3,405bp downstream of the Betaine-homocystein S-methyltransferase 2 gene

(*BHMT2*, **Fig. 1b**), a gene whose product is involved in choline metabolism during

development[56]. Other protein-coding genes that are closest to the lead SNPs include those

involved in calcium signaling (*CAMK2N2* and *INPP5A*) and metabolism and transcription

regulation (*GALC*, *KLF3* and *KLHL38*), both processes are implicated in biological ageing[57]. In

**Supplementary Table S5** we present detailed annotations of biological functions to each gene.

We further annotated these identified SNPs to nearby genes and regulatory elements

(**Methods**). Most of the associated SNPs are in non-coding regions such as intergenic, intron

or untranslated regions (**Supplementary Figs. S3** and **S4**). Using the default parameters in

FUMA[29], 54 unique genes were found to be implied by these significant associations by

genomic position. The expression levels of these genes in the 54 tissue types from the GTEx

v8 project[33] showed three remarkable patterns (**Fig. 1c**). The first set of genes expressed highly

across almost all 54 tissues; the second set of genes showed low expression levels in most

tissue types; and the last set, including eight genes, was highly expressed only in brain tissue

types (**Fig. 1c**), for example *MAPT*, *GFAP*, and the Homeobox protein gene *NKX6-2*. These

results suggest that BAG encodes coordinated physiological processes implicating both the

brain and the peripheral systems.

To nominate causal variants in each locus we performed statistical fine-mapping[31] for

regions around each lead SNP in **Table 1** (**Methods**). Except for the locus on chromosome 14

which was not resolvable, all loci clearly indicated that the 95% credible sets suggest a causal

model with one causal SNP, instead of two, *i.e.*, the posterior probability for the 1-SNP set

were larger than those of the 2-SNP sets (**Supplementary Table S16**). Furthermore, four

credible sets indicated that the lead SNPs were also the causal ones (posterior inclusion

probability (PPI_1) > 0.05 and >PPI of the second most probable SNP(PPI_2)) (**Methods**;

**Supplementary Table 16**) but identifying the causal SNP for the remaining were difficult. For

example, the *MAPT* locus on chromosome 17 and the *RUNX2* locus on chromosome 6 showed

two SNPs having almost equal and small PPIs (*i.e.*, <=0.05), indicating that the true causal

variants may be some untyped rare ones not investigated in this study. The clearest signal

comes from the regions on chromosome 3 and 5, where the PPIs for the lead SNPs were much

larger than that for the second most probable causal SNPs.

269  We observed nominally significant genetic correlation between BAG and AD that did

270 not survive FDR-correction (r=0.23, SE=0.1, p=0.02, FDR adjusted-p=0.13) and no significant

271 associations with any other of the four disorders (**Fig. 2a**). SNP heritability estimates for the

272 five disorders were all significant but varied greatly; SCZ showed the largest (0.34, SE=0.01)

273 and AD showed the lowest (0.01, SE=0.005) estimates. Bidirectional conditional QQ plots (**Fig.**

274 **2b**-**d; Supplementary Figs. S6** and **S7**) showed that there was noticeable genetic enrichment

275 for BIP conditional on BAG but not in the reverse direction. For AD and PD, both directions

276 showed clear enrichment, surprisingly for PD which did not show significant genetic

277 correlation with BAG (r=-0.07, p=0.42).

278  We then performed extensive MR analyses using six different models to examine the

279 existence of cause-effect relations between BAG and the five disorders (**Methods**). **Figure 3a**

280 shows that BAG was only causally associated with PD, *i.e.*, four out of the six MR models

281 showed a negative relation with varying effect sizes (all with adjusted p <0.05). One year

282 increase in genetically predicted BAG was estimated to reduce the risk of PD by a log odds

283 ratio from 1.4 (by Egger regression) to 0.02 (by MR-RAPS) (**Supplementary Table S15**). In the

284 reverse direction (*i.e.*, disorders as exposure), increased genetic risk for AD and BIP were

285 causally associated with increased BAG (30 and 55 SNPs used as instruments, respectively);

286 these estimated causal effects on BAG were relatively larger for AD than BIP (**Fig. 3b;**

287 **Supplementary Table S16**).

288  A close investigation into the scatter plots of instrumental SNPs showed that the causal

289 effect of AD on BAG was primarily driven by a SNP (rs59007384) in the APOE region, which

290 was not identified as a horizontal pleiotropic instrument by MR-PRESSO (outlier test p>0.05)

(**Fig. 3c**); there were no extreme instruments identified for the BIP to BAG relation by MR-

PRESSO (**Fig. 3d**) but Egger-regression indicated existence of horizontal pleiotropy (Egger

intercept test: p=0.017). The causal effects of BAG on PD were primarily driven by two SNPs

in the inversion region on chromosome 17, effective alleles of these SNPs were associated

with higher BAG and lower risk of PD (**Fig. 3e**). SNPs in the same region also drove the negative

causal relation (not significant) from PD to BAG (**Fig. 3f**). However, both SNPs were flagged as

horizontal pleiotropic instruments by MR-PRESSO (p<0.05) and Egger-regression (Egger

intercept test: p=0.03 and 0.008, respectively). Therefore, the observed negative relations

between BAG and PD are less likely to be causal.

We used the GWAS results for height of European samples and cross-ancestry MR

analysis to corroborate the identified causal relations (**Methods**). We found no causal effect

between BAG and height with any of the MR methods employed (all p > 0.05). Therefore, our

observed AD and BIP to BAG relations are less likely to be driven by population stratification,

*i.e.*, both the exposure and outcome data originating from the same ancestry group. There

was also no significant cross-ancestral causal effect detected using AD data from Japanese or

African samples (IVW p=0.74, 0,85, respectively), and BIP data from the Japanese sample to

BAG (beta=0.10, p=0.13).

**Discussion**

Combining the advantages of large samples and advanced models for brain age prediction, we

confirmed that BAG is a heritable and polygenic trait, and estimated the genetic pleiotropy

and causal genetic relations with major brain and mental disorders. We identified seven novel

loci associated with BAG, in addition to confirming the previously reported *MAPT* loci[18, 19].

While MR indicated that increased genetic risk for AD or BIP may be causally associated with

higher BAG, our results demonstrate that individual variability and previously reported case-

control differences in BAG only to a marginal degree should be attributed to the genetic risk

of the respective diseases.

Functional annotation of the genes linked to the identified loci confirms that

deviations in BAG are linked to complex processes encompassing multiple biological systems[20].

While earlier work observed this variety when investigating different multimodal aspects of

imaging data linked to brain aging, our findings suggest it also exists when looking at a singular

BAG computed from only T1-weighted structural imaging. Our coarse division of the implied

54 genes into three groups indicates that only eight genes are specifically expressed in brain

tissues. The remaining genes were either expressed in abundance across all tissue types

tested, including the brain, or expressed at very low levels across all tissues. Nonetheless, the

proteins coded by these non-brain specific genes have been implicated in brain-related

disorders or traits (**Supplementary Table S5**). For example, among the genes we found to be

expressed across all tissue types (group 1), mutations in *AP2M1* have been linked to epilepsy,

intellectual developmental disorder, and seizures[58]; among the genes expressed in low levels

across tissues (group 2), *STH* has been associated with frontotemporal dementia and

17q21.31 duplication syndrome[59, 60]. In addition, although our analysis revealed no significant

pathway enrichment, these 54 genes contribute to biological functions that include calcium

signaling, protein metabolism, DNA damage repair and general innate immune defense. Thus,

our analyses highlight the role of these diverse sets of processes affecting the brain

throughout life.

Prior work has shown higher BAG in patients with a multitude of disorders compared

to healthy controls[5, 6, 8, 9, 11], and has documented partly overlapping genetic associations

between BAG and clinical conditions[6] . However, the causal effects have remained unclear.

Our MR approach revealed that genetically predicted risks for AD or BIP were causally

associated with increased BAG. However, these relations were only weakly supported by

genetic correlation analysis. One possible explanation for this weaker support from genome

wide signals (genetic correlation) in contrast to MR (significant associations only) might be

due to heterogeneous genetic correlations across the genome, *i.e.* some genomic regions

show positive correlations while others show negative correlations[61, 62]. In such a scenario,

the net genetic correlations between the two traits are expected to be lower than regional

correlations.

The causal effect of genetically predicted risk to AD on BAG was small but consistent

in directions across the six MR models, four of which were significant after multiple-testing

correction. For BIP, although four models showed significant effects, the CAUSE model

suggested an opposite direction of effect to the other five models. Thus, we advise careful

interpretation of this result. Our attempts of testing across ancestral group causal relations

led to largely null fundings for the AD to BAG relations. We believe these non-significant

fundings are largely due to the lack of statistical power in the non-European GWAS[51-53].

The observed causal relations between genetically predicted risk of brain disorders

and BAG are intriguing. One possible interpretation is that overt changes in the brain incurred

by the disorders contribute to accelerated aging. Another possibility may be that lifestyle and

health-related behaviors of patients with clinical conditions such as AD and BIP, *e.g.*,

medication[63], may increase brain age. Yet another is that genetic variation drives early life

changes in brain structure which contribute to both phenotypes later in life. Given the

comparable sample sizes to the GWAS of AD and BIP and the widely observed clinical

correlations, surprisingly, no genetic nor causal relations of SCZ and MDD with BAG were

found. On the one hand this may suggest that previously reported case-control differences do

not reflect causal relations, but rather a combination of indirect and confounding factors. For

example, smoking and physical exercise have been associated both with MDD and SCZ[64-67] and

brain age[5, 66]. Alternatively, it has been shown that both BAG[20] and psychiatric disorders are

highly heterogeneous phenotypes[68, 69], and thus further identification and characterization of

the causal relations may require even larger, and carefully screened, samples. It is also worth

noting that while the sample sizes for the disorders are large, the one underlying our BAG

GWAS is relatively small. Thus, our null findings in the direction from BAG to disorders may be

due to too weak instruments[70].

Our initial results showed weak evidence of a causal relation between BAG and PD,

corroborating two recent studies which reported a weaker correlation between BAG and PD

[71, 72]. Striking patterns of enrichment between the two were shown in the conditional QQ plots

and four out of six MR models indicated that genetically predicted BAG may have protective

effect from PD. However, we found that these relations were completely caused by the *MAPT*

gene region on chromosome 17: after removing chromosome 17 from our analyses, no

enrichment was observed in either direction (**Supplementary Fig. S8**). In addition,

instrumental SNPs in this region were detected by MR-PRESSO as horizontal pleiotropic SNPs,

*i.e.*, affecting BAG and PD through independent biological pathways. Reperforming MR

analysis excluding these outlier SNPs confirmed null causal relations. Thus, we conclude that

we found no evidence for causal relations between genetically predicted risk for PD and BAG.

Our analytic procedures also highlight the importance of triangulation and converging

evidence in causal inference analysis[73].

While the present study advances current knowledge regarding the genetic

architecture of and causal contributions to BAG, the results should be interpreted with caution.

Although we confirm previously reported genetic associations with BAG, e.g., the *MAPT* gene

locus[18, 19], our sample overlaps with previous ones—which were also based on UK Biobank

data. We attempted replicating our findings in three independent but small samples (n ranges

from 321 to 702; **Supplementary Analysis** and **Table S4**) but no clear replications were

achieved. Therefore, independent large-scale samples are needed for replication. We used a

simple voting schema across six different MR models to infer causal relations between

genetically predicted BAG and brain disorders. Furthermore, as we only identified eight

independent loci showing significant associations to BAG, other models[74] that require large

number of genome-wide significant instruments were considered not applicable. However, it

should be noted our simple voting approach may not be the most efficient strategy for

identifying causal effects. Formal development of ensemble methods, such as bagging[75], may

provide better grounds for precise interpretation. Furthermore, our BAG GWAS is still smaller

than GWAS performed for the disorders, which may partly explain the lack of causal effects of

BAG on brain disorders. Therefore, to increase our confidence in the identified relations, large-

scale data for BAG, and replications in independent datasets are needed. Relatedly, our

estimation of brain age was based on cross-sectional samples, which makes its interpretation

non-trivial[76], and studies built on longitudinal data could help disentangle its complexities.

Finally, although we refer to our brain age estimation in general terms, it is important to

reaffirm that it is based on T1-weighted imaging data. The brain is a complex and

heterogeneous organ, and different imaging modalities are known to capture different

aspects of the naturally occurring variation. Thus, studies relying on other modalities, either

independently or in combination, could reveal a broader set of associations[77].

In conclusion, the present study increases the yield of genetic associations with brain

age to eight genomic loci; implicated genes indicate involvement of calcium signaling, DNA

damage repair, protein metabolism, and general innate immune defense. Our analysis did not

provide evidence of a causal relationship between BAG and the included clinical conditions,

and their interactions remain unclear.

**Conflict of Interests**

All authors declared no conflict of interests.

**Funding**

This study is supported by Norwegian Research Council (No. 223273, 298646, 300767,

302854), the UiO:Life Science Convergence environment, University of Oslo, Norway

(4MENT), the South-Eastern Norway Regional Health Authority (2019101), KG Jebsen

Stiftelsen, and the European Research Council under the European Union's Horizon 2020

research and Innovation program (ERC StG, Grant 802998).

**Author contributions**

EL, TW, and YW designed this study; EL, DVP, OF, AAS, OI, AMG and YW performed data

analysis; EL, DVP, JMR, OI, TK, LTW, OOA, TW, BT, SMS, and YW interpreted the results; EL,

DVP, JMR, OI, YW prepared the first draft of the manuscripts; All authors contributed and

approved the final draft.

**Acknowledgement**

This research has been conducted using the UK Biobank Resource under Application

Number 27412. We thank the computational resources provided by UNINETT Sigma2-the

National Infrastructure for High Performance Computing and Data Storage in Norway – with

project no. (nn9769k/ns9769k)**,** the PGC consortium and the International Parkinson

Disease Genomics Consortium (IPDGC) for sharing of their GWAS results.

References

1.    Franke K, Gaser C. Ten Years of BrainAGE as a Neuroimaging Biomarker of Brain
Aging: What Insights Have We Gained? *Frontiers in Neurology* 2019; **10:** 789.

2.    Cole JH, Franke K. Predicting Age Using Neuroimaging: Innovative Brain Ageing
Biomarkers. *Trends in neurosciences* 2017; **40**(12)**:** 681-690.

3.    Franke K, Luders E, May A, Wilke M, Gaser C. Brain maturation: Predicting individual
BrainAGE in children and adolescents using structural MRI. *NeuroImage* 2012; **63**(3)**:**
1305-1312.

4.    Smith SM, Vidaurre D, Alfaro-Almagro F, Nichols TE, Miller KL. Estimation of brain
age delta from brain imaging. *NeuroImage* 2019; **200:** 528-539.

5.    Leonardsen EH, Peng H, Kaufmann T, Agartz I, Andreassen OA, Celius EG *et al.* Deep
neural networks learn general and clinically relevant representations of the ageing
brain. *NeuroImage* 2022; **256:** 119210.

6.    Kaufmann T, van der Meer D, Doan NT, Schwarz E, Lund MJ, Agartz I *et al.* Common
brain disorders are associated with heritable patterns of apparent aging of the brain.
*Nature Neuroscience* 2019; **22**(10)**:** 1617-1623.

7.    Cole JH, Ritchie SJ, Bastin ME, Valdés Hernández MC, Muñoz Maniega S, Royle N *et
al.* Brain age predicts mortality. *Molecular Psychiatry* 2018; **23**(5)**:** 1385-1392.

8.    Gaser C, Franke K, Klöppel S, Koutsouleris N, Sauer H, Alzheimer's Disease
Neuroimaging I. BrainAGE in Mild Cognitive Impaired Patients: Predicting the
Conversion to Alzheimer's Disease. *PloS one* 2013; **8**(6)**:** e67346.

9.    Schnack HG, van Haren NEM, Nieuwenhuis M, Hulshoff Pol HE, Cahn W, Kahn RS.
Accelerated Brain Aging in Schizophrenia: A Longitudinal Pattern Recognition Study.
*American Journal of Psychiatry* 2016; **173**(6)**:** 607-616.

10.   Constantinides C, Han LK, Alloza C, Antonucci L, Arango C, Ayesa-Arriola R *et al.* Brain
ageing in schizophrenia: evidence from 26 international cohorts via the ENIGMA
Schizophrenia consortium. *medRxiv* 2022**:** 2022.2001.2010.21267840.

11.   Han LKM, Dinga R, Hahn T, Ching CRK, Eyler LT, Aftanas L *et al.* Brain aging in major
depressive disorder: results from the ENIGMA major depressive disorder working
group. *Molecular Psychiatry* 2021; **26**(9)**:** 5124-5139.

12.   Elliott ML, Belsky DW, Knodt AR, Ireland D, Melzer TR, Poulton R *et al.* Brain-age in
midlife is associated with accelerated biological aging and cognitive decline in a
longitudinal birth cohort. *Molecular Psychiatry* 2021; **26**(8)**:** 3829-3838.

13.    Kuhn T, Kaufmann T, Doan NT, Westlye LT, Jones J, Nunez RA *et al.* An augmented
481           aging process in brain white matter in HIV. *Human brain mapping* 2018; **39**(6)**:** 2532-
482           2540.
483
484    14.    Cole JH, Underwood J, Caan MWA, De Francesco D, van Zoest RA, Leech R *et al.*
485           Increased brain-predicted aging in treated HIV disease. *Neurology* 2017; **88**(14)**:**
486           1349-1357.
487
488    15.    Steffener J, Habeck C, O'Shea D, Razlighi Q, Bherer L, Stern Y. Differences between
489           chronological and brain age are related to education and self-reported physical
490           activity. *Neurobiology of Aging* 2016; **40:** 138-144.
491
492    16.    Wrigglesworth J, Ward P, Harding IH, Nilaweera D, Wu Z, Woods RL *et al.* Factors
493           associated with brain ageing - a systematic review. *BMC neurology* 2021; **21**(1)**:** 312.
494
495    17.    Cole JH, Poudel RPK, Tsagkrasoulis D, Caan MWA, Steves C, Spector TD *et al.*
496           Predicting brain age with deep learning from raw imaging data results in a reliable
497           and heritable biomarker. *NeuroImage* 2017; **163:** 115-124.
498
499    18.    Jonsson BA, Bjornsdottir G, Thorgeirsson TE, Ellingsen LM, Walters GB, Gudbjartsson
500           DF *et al.* Brain age prediction using deep learning uncovers associated sequence
501           variants. *Nature Communications* 2019; **10**(1)**:** 5409.
502
503    19.    Ning K, Zhao L, Matloff W, Sun F, Toga AW. Association of relative brain age with
504           tobacco smoking, alcohol consumption, and genetic variants. *Scientific Reports* 2020;
505           **10**(1)**:** 10.
506
507    20.    Smith SM, Elliott LT, Alfaro-Almagro F, McCarthy P, Nichols TE, Douaud G *et al.* Brain
508           aging comprises many modes of structural and functional change with distinct
509           genetic and biophysical associations. *eLife* 2020; **9:** e52677.
510
511    21.    Smith GD, Ebrahim S. 'Mendelian randomization': can genetic epidemiology
512           contribute to understanding environmental determinants of disease? *International
513           journal of epidemiology* 2003; **32**(1)**:** 1-22.
514
515    22.    Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D *et al.* The MR-Base
516           platform supports systematic causal inference across the human phenome. *eLife*
517           2018; **7**.
518
519    23.    Kolbeinsson A, Filippi S, Panagakis Y, Matthews PM, Elliott P, Dehghan A *et al.*
520           Accelerated MRI-predicted brain ageing and its associations with cardiometabolic
521           and brain disorders. *Scientific Reports* 2020; **10**(1)**:** 19940.
522
523    24.    Ségonne F, Dale AM, Busa E, Glessner M, Salat D, Hahn HK *et al.* A hybrid approach
524           to the skull stripping problem in MRI. *NeuroImage* 2004; **22**(3)**:** 1060-1075.
525

526   25.   Jenkinson M, Beckmann CF, Behrens TEJ, Woolrich MW, Smith SM. FSL. *NeuroImage*
527         2012; **62**(2)**:** 782-790.
528

529   26.   Jenkinson M, Smith S. A global optimisation method for robust affine registration of
530         brain images. *Medical Image Analysis* 2001; **5**(2)**:** 143-156.
531

532   27.   Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K *et al.* The UK Biobank
533         resource with deep phenotyping and genomic data. *Nature* 2018; **562**(7726)**:** 203-
534         209.
535

536   28.   Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation
537         PLINK: rising to the challenge of larger and richer datasets. *Gigascience* 2015; **4:** 7.
538

539   29.   Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and
540         annotation of genetic associations with FUMA. *Nature Communications* 2017; **8**(1)**:**
541         1826.
542

543   30.   McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Thormann A *et al.* The Ensembl
544         Variant Effect Predictor. *Genome Biology* 2016; **17**(1)**:** 122.
545

546   31.   Benner C, Spencer CC, Havulinna AS, Salomaa V, Ripatti S, Pirinen M. FINEMAP:
547         efficient variable selection using summary data from genome-wide association
548         studies. *Bioinformatics* 2016; **32**(10)**:** 1493-1501.
549

550   32.   Yap CX, Henders AK, Alvares GA, Wood DLA, Krause L, Tyson GW *et al.* Autism-
551         related dietary preferences mediate autism-gut microbiome associations. *Cell* 2021;
552         **184**(24)**:** 5916-5931.e5917.
553

554   33.   Consortium G. Human genomics. The Genotype-Tissue Expression (GTEx) pilot
555         analysis: multitissue gene regulation in humans. *Science* 2015; **348**(6235)**:** 648-660.
556

557   34.   Maglott D, Ostell J, Pruitt KD, Tatusova T. Entrez Gene: gene-centered information at
558         NCBI. *Nucleic Acids Research* 2011; **39**(suppl_1)**:** D52-D57.
559

560   35.   Boutet E, Lieberherr D, Tognolli M, Schneider M, Bairoch A. UniProtKB/Swiss-Prot. In:
561         Edwards D (ed). *Plant Bioinformatics: Methods and Protocols*. Humana Press:
562         Totowa, NJ, 2007, pp 89-112.
563

564   36.   Trubetskoy V, Pardiñas AF, Qi T, Panagiotaropoulou G, Awasthi S, Bigdeli TB *et al.*
565         Mapping genomic loci implicates genes and synaptic biology in schizophrenia. *Nature*
566         2022;**604**(7906):502-508.
567

568   37.   Mullins N, Forstner AJ, O'Connell KS, Coombes B, Coleman JRI, Qiao Z *et al.* Genome-
569         wide association study of more than 40,000 bipolar disorder cases provides new
570         insights into the underlying biology. *Nature Genetics* 2021; **53**(6)**:** 817-829.
571

572 38. Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoui A *et al.*
573 Genome-wide association analyses identify 44 risk variants and refine the genetic
574 architecture of major depression. *Nature Genetics* 2018; **50**(5)**:** 668-681.
575

576 39. Jansen IE, Savage JE, Watanabe K, Bryois J, Williams DM, Steinberg S *et al.* Genome-
577 wide meta-analysis identifies new loci and functional pathways influencing
578 Alzheimer's disease risk. *Nature Genetics* 2019; **51**(3)**:** 404-413.
579

580 40. Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang D *et al.*
581 Identification of novel risk loci, causal insights, and heritable risk for Parkinson's
582 disease: a meta-analysis of genome-wide association studies. *The Lancet Neurology*
583 2019; **18**(12)**:** 1091-1102.
584

585 41. Bulik-Sullivan B, Finucane HK, Anttila V, Gusev A, Day FR, Loh PR *et al.* An atlas of
586 genetic correlations across human diseases and traits. *Nature Genetics* 2015; **47**(11)**:**
587 1236-1241.
588

589 42. Lo MT, Wang Y, Kauppi K, Sanyal N, Fan CC, Smeland OB *et al.* Modeling prior
590 information of common genetic variants improves gene discovery for neuroticism.
591 *Human Molecular Genetics* 2017; **26**(22)**:** 4530-4539.
592

593 43. Chen CH, Wang Y, Lo MT, Schork A, Fan CC, Holland D *et al.* Leveraging genome
594 characteristics to improve gene discovery for putamen subcortical brain structure.
595 *Scientific Reports* 2017; **7**(1)**:** 15736.
596

597 44. Relton CL, Davey Smith G. Two-step epigenetic Mendelian randomization: a strategy
598 for establishing the causal role of epigenetic processes in pathways to disease.
599 *International journal of epidemiology* 2012; **41**(1)**:** 161-176.
600

601 45. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in
602 Mendelian Randomization with Some Invalid Instruments Using a Weighted Median
603 Estimator. *Genetic Epidemiology* 2016; **40**(4)**:** 304-314.
604

605 46. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid
606 instruments: effect estimation and bias detection through Egger regression.
607 *International journal of epidemiology* 2015; **44**(2)**:** 512-525.
608

609 47. Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy
610 in causal relationships inferred from Mendelian randomization between complex
611 traits and diseases. *Nature Genetics* 2018; **50**(5)**:** 693-698.
612

613 48. Zhao Q, Wang J, Hemani G, Bowden J, Small DS. Statistical inference in two-sample
614 summary-data Mendelian randomization using robust adjusted profile score. *Annals
615 Statistics* 2020; **48**(3)**:** 1742-1769.
616

617 49. Morrison J, Knoblauch N, Marcus JH, Stephens M, He X. Mendelian randomization
618 accounting for correlated and uncorrelated pleiotropic effects using genome-wide
619 summary statistics. *Nature Genetics* 2020; **52**(7)**:** 740-747.
620

621 50. Wood AR, Esko T, Yang J, Vedantam S, Pers TH, Gustafsson S *et al.* Defining the role
622 of common variation in the genomic and biological architecture of adult human
623 height. *Nature Genetics* 2014; **46**(11)**:** 1173-1186.
624

625 51. Shigemizu D, Mitsumori R, Akiyama S, Miyashita A, Morizono T, Higaki S *et al.* Ethnic
626 and trans-ethnic genome-wide association studies identify new loci influencing
627 Japanese Alzheimer's disease risk. *Translational psychiatry* 2021; **11**(1)**:** 151.
628

629 52. Kunkle BW, Schmidt M, Klein H-U, Naj AC, Hamilton-Nelson KL, Larson EB *et al.* Novel
630 Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the
631 African Genome Resources Panel: A Meta-analysis. *JAMA neurology* 2021; **78**(1)**:**
632 102-113.
633

634 53. Ikeda M, Takahashi A, Kamatani Y, Okahisa Y, Kunugi H, Mori N *et al.* A genome-wide
635 association study identifies two novel susceptibility loci and trans population
636 polygenicity associated with bipolar disorder. *Molecular Psychiatry* 2018; **23**(3)**:** 639-
637 647.
638

639 54. Sanderson E, Richardson TG, Hemani G, Davey Smith G. The use of negative control
640 outcomes in Mendelian randomization to detect potential population stratification.
641 *International journal of epidemiology* 2021; **50**(4)**:** 1350-1361.
642

643 55. Lam K, Zhang DE. RUNX/CBF Transcription Factors☆. *Reference Module in*
644 *Biomedical Sciences*. Elsevier2015.
645

646 56. Kotb M, Geller AM. Methionine adenosyltransferase: Structure and function.
647 *Pharmacology & therapeutics* 1993; **59**(2)**:** 125-143.
648

649 57. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The Hallmarks of Aging.
650 *Cell* 2013; **153**(6)**:** 1194-1217.
651

652 58. Helbig I, Lopez-Hernandez T, Shor O, Galer P, Ganesan S, Pendziwiat M *et al.* A
653 Recurrent Missense Variant in AP2M1 Impairs Clathrin-Mediated Endocytosis and
654 Causes Developmental and Epileptic Encephalopathy. *The American Journal of*
655 *Human Genetics* 2019; **104**(6)**:** 1060-1072.
656

657 59. Mc Cormack A, Taylor J, Te Weehi L, Love DR, George AM. A Case of 17q21.31
658 Microduplication and 7q31.33 Microdeletion, Associated with Developmental Delay,
659 Microcephaly, and Mild Dysmorphic Features. *Case Reports in Genetics* 2014; **2014:**
660 658570.
661

662   60.   Arbogast T, Iacono G, Chevalier C, Afinowi NO, Houbaert X, van Eede MC *et al.*
663         Mouse models of 17q21.31 microdeletion and microduplication syndromes highlight
664         the importance of Kansl1 for cognition. *PLOS Genetics* 2017; **13**(7)**:** e1006886.
665

666   61.   Frei O, Holland D, Smeland OB, Shadrin AA, Fan CC, Maeland S *et al.* Bivariate causal
667         mixture model quantifies polygenic overlap between complex traits beyond genetic
668         correlation. *Nature Communications* 2019; **10**(1)**:** 2417.
669

670   62.   van Rheenen W, Peyrot WJ, Schork AJ, Lee SH, Wray NR. Genetic correlations of
671         polygenic disease traits: from theory to practice. *Nature Reviews Genetics* 2019;
672         **20**(10)**:** 567-581.
673

674   63.   Van Gestel H, Franke K, Petite J, Slaney C, Garnham J, Helmick C *et al.* Brain age in
675         bipolar disorders: Effects of lithium treatment. *Australian & New Zealand Journal of*
676         *Psychiatry* 2019; **53**(12)**:** 1179-1188.
677

678   64.   Pasco JA, Williams LJ, Jacka FN, Ng F, Henry MJ, Nicholson GC *et al.* Tobacco smoking
679         as a risk factor for major depressive disorder: population-based study. *British Journal*
680         *of Psychiatry* 2008; **193**(4)**:** 322-326.
681

682   65.   Winterer G. Why do patients with schizophrenia smoke? *Current opinion in*
683         *psychiatry* 2010; **23**(2).
684

685   66.   Sanders A-M, Richard G, Kolskår K, Ulrichsen KM, Kaufmann T, Alnæs D *et al.* Linking
686         objective measures of physical activity and capability with brain structure in healthy
687         community dwelling older adults. *NeuroImage: Clinical* 2021; **31:** 102767.
688

689   67.   Brokmeier LL, Firth J, Vancampfort D, Smith L, Deenik J, Rosenbaum S *et al.* Does
690         physical activity reduce the risk of psychosis? A systematic review and meta-analysis
691         of prospective studies. *Psychiatry research* 2020; **284:** 112675.
692

693   68.   Wolfers T, Doan NT, Kaufmann T, Alnaes D, Moberget T, Agartz I *et al.* Mapping the
694         Heterogeneous Phenotype of Schizophrenia and Bipolar Disorder Using Normative
695         Models. *JAMA Psychiatry* 2018; **75**(11)**:** 1146-1155.
696

697   69.   Wolfers T, Rokicki J, Alnæs D, Berthet P, Agartz I, Kia SM *et al.* Replicating extensive
698         brain structural heterogeneity in individuals with schizophrenia and bipolar disorder.
699         *Human brain mapping* 2021; **42**(8)**:** 2546-2555.
700

701   70.   Taschler B, Smith SM, Nichols TE. Causal inference on neuroimaging data with
702         Mendelian randomisation. *NeuroImage* 2022; **258:** 119385.
703

704   71.   Eickhoff CR, Hoffstaedter F, Caspers J, Reetz K, Mathys C, Dogan I *et al.* Advanced
705         brain ageing in Parkinson's disease is related to disease duration and individual
706         impairment. *Brain Communications* 2021; **3**(3)**:** fcab191.
707

708    72.    Charissé D, Erus G, Pomponio R, Gorges M, Schmidt N, Schneider C *et al.* Brain age
709           and Alzheimer's-like atrophy are domain-specific predictors of cognitive impairment
710           in Parkinson's disease. *Neurobiology of aging* 2022; **109:** 31-42.
711

712    73.    Lawlor DA, Tilling K, Davey Smith G. Triangulation in aetiological epidemiology.
713           *International journal of epidemiology* 2016; **45**(6)**:** 1866-1886.
714

715    74.    Sanderson E, Glymour MM, Holmes MV, Kang H, Morrison J, Munafò MR *et al.*
716           Mendelian randomization. *Nature Reviews Methods Primers* 2022; **2**(1)**:** 6.
717

718    75.    Büchlmann P, Yu B. Analyzing Bagging. *The Annals of Statistics* 2002; **30**(4)**:** 927-961.
719

720    76.    Vidal-Pineiro D, Wang Y, Krogsrud SK, Amlien IK, Baaré WFC, Bartres-Faz D *et al.*
721           Individual variations in 'brain age' relate to early-life factors more than to
722           longitudinal brain change. *eLife* 2021; **10:** e69995.
723

724    77.    Rokicki J, Wolfers T, Nordhøy W, Tesli N, Quintana DS, Alnæs D *et al.* Multimodal
725           imaging improves brain age prediction and reveals distinct abnormalities in patients
726           with psychiatric and neurological disorders. *Human brain mapping* 2021; **42**(6)**:**
727           1714-1726.
728

FIGURE LEGENDS

**Figure 1 Genetic associations for brain age gap.**

**a.** The Manhattan plot of meta-analyzed association results for brain age gap (BAG).

Chromosome numbers are shown on x axis, -log10 association p values on y axis and lead

SNP rs-numbers in the plot. **b.** Region plots for each of the eight associated regions. Genes

located in each region are shown below each figure. Linkage disequilibrium r-squared values

are indicated by colors; and recombination frequences by curves. **c.** Expression levels of the

annotated genes across tissues analyzed by the GTEx v8 study. Colors indicate average log2

transformed expression level in each tissue.

**Figure 2 Polygenic genetic overlap between brain age gap and disorders.**

**a.** Genetic correlation between brain age gap and disorders computed by ldsc. SNP

heritability and its standard error are indicated. **b-d.** Conditional QQ plot between brain age

gap and disorders in both directions. Colors are used to indicate different association

strength to the conditioned traits, i.e., the ones indicated after the vertical bar in each

figure. Dashed diagonal lines indicate expected null distributions.  Abbreviations used: AD,

Alzheimer's disease; BIP, bipolar disorder; MDD, major depression disorder; PD, Parkinson's

disease; SCZ, schizophrenia.

**Figure 3 Causal inference between brain age gap and disorders.**

**a.** Causal effect of brain age gap (BAG) on risk of disorders; **b.**  Causal effect of genetic risk of

disorders on BAG. Colors indicate different models; triangle indicates significant effect after

false discovery correction. Estimated standard errors for each effect are aslo shown. **c.**

Scatter plots of SNP effects on AD (x axis) and BAG (y axis). **d.** Scatter plots of SNP effects on

BIP (x axis) and BAG (y axis). **e.** Scatter plots of SNP effects BAG (x axis) and PD (y axis). **f.**

Scatter plots of SNP effects on PD (x axis) and BAG (y axis). Causal effects estimated by the

five models (except CAUSE) are shown by fitted lines; slopes of these lines indicate causal

effect sizes. Exceptional SNPs are marked by boxes which include SNP rs-numbers and

genome location in th hg19 coordinates. Abbreviation used: AD, Alzheimer's disease; BIP,

bipolar disorder; MDD, major depression disorder; PD, Parkinson's disease; SCZ,

schizophrenia.

760
761

763 **Table 1 Genomic loci associated with BAG.**

| Locus | Lead SNP | POS | Gene | A1 | A2 | Beta | I² | P |
|---|---|---|---|---|---|---|---|---|
| Chr3:183892867-183975709 | rs73185796 | 183975709 | CAMK2N2/ECE2 | T | G | -0.29 | 0.0 | $2.53 \times 10^{-8}$ |
| Chr4:38591172-38779512 | rs13132853 | 38680015 | KLF3 | G | A | 0.23 | 0.0 | $2.34 \times 10^{-18}$ |
| Chr5:78388694-78451813 | rs79107704 | 78388694 | BHMT2 | A | G | 0.63 | 0.0 | $1.65 \times 10^{-8}$ |
| Chr6:45407654-45511945 | rs2790102 | 45432214 | RUNX2 | A | G | -0.15 | 0.0 | $8.92 \times 10^{-9}$ |
| Chr8:124661974-124682971 | rs7461069 | 124669029 | KLHL38 | A | G | -0.17 | 0.0 | $1.57 \times 10^{-8}$ |
| Chr10:134544247-134597265 | rs4880424 | 134584577 | INPP5A | T | C | 0.16 | 64.95 | $3.69 \times 10^{-8}$ |
| Chr14: 88391116-88556525 | rs17203398 | 88449847 | GALC | C | G | -0.16 | 40.97 | $1.42 \times 10^{-10}$ |
| Chr17: 43101281-44863413 | rs2106786 | 43919096 | MAPT | G | A | 0.29 | 0.0 | $1.87 \times 10^{-23}$ |

764 Eight independent genomic loci significantly associated with brain age gap (BAG). Lead SNP

765 rs-number, genomic position (in hg19 coordinates), effective allele (A1), the other allele

766 (A2), effect size (Beta), meta-analysis heterogeneity ($I^2$), association strength (p value, P).

768
769

770    FIGURES
771    Figure 1

772
773

774    Figure 2

775
776
777

778    Figure 3

780